NOVATO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with the company to allow him to be able to devote more of his time to personal endeavors related to rare diseases. Dr. Kakkis will continue to be a consultant for the company for the foreseeable future.
"I am extremely grateful to have been part of this organization over the last ten years and to have been part of developing three novel treatments for rare genetic diseases. I would like to thank all of the patients, doctors and, particularly, the BioMarin employees that have helped me in those efforts. I am looking forward to the opportunity to devote additional time to developing an institute for rare diseases and legislation to support ultra-orphan drug development," said Dr. Kakkis.
"Emil has been an invaluable part of the leadership team here at BioMarin
and we are sorry to see him leave. He has been instrumental in the
development of all of BioMarin's products, dating back to the very early work
that he did on Aldurazyme while he was on the faculty of
Dr. Kakkis joined BioMarin in September 1998. Prior to joining BioMarin,
he was an assistant professor at th
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2008 PR Newswire.
All rights reserved